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Objectives: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in disease
modifying antirheumatic drug (DMARD) refractory patients with longstanding, active rheumatoid arthritis
(RA).
Methods: During a 12 week, double blind, placebo controlled study, 284 patients were randomly
allocated to receive weekly subcutaneous injections of adalimumab 20 mg (n = 72), 40 mg (n = 70), or
80 mg (n = 72) or placebo (n = 70) without concomitant DMARDs.
Results: Adalimumab significantly improved the signs and symptoms of RA for all efficacy measures.
ACR20 responses with adalimumab were significant at each assessment versus placebo (p(0.01).
Additionally, ACR responses with adalimumab were achieved more rapidly than with placebo, with 82/
115 (71%) of the ultimate ACR20 response rate to adalimumab treatment achieved at week 2. At week 12,
for adalimumab 20, 40, and 80 mg, ACR20 response rates were 50.7%, 57.1%, and 54.2%, respectively,
versus 10.0% for placebo (p(0.001 for all comparisons); ACR50 rates were 23.9%, 27.1%, and 19.4%,
respectively, versus 1.4% for placebo (p(0.001 for all comparisons); and ACR70 rates were 11.3%,
10.0%, and 8.3%, respectively, versus 0.0% for placebo (p(0.05 for all comparisons). All adalimumab
doses significantly improved all ACR core criteria at all assessments. The 40 mg and 80 mg doses
provided similar benefit. Adalimumab at all doses was generally well tolerated, with only mild or
moderate adverse events. Completion rates were 87% for adalimumab and 67% for placebo.
Conclusions: Adalimumab given as monotreatment to patients with longstanding, severe RA refractory to
traditional DMARDs produced a rapid, sustained response and was safe and well tolerated, with no dose
limiting side effects.
R
heumatoid arthritis (RA) is a chronic, systemic disorder
that affects about 0.5–1.0% of adults in Western nations
and is 2.5 times more prevalent among women than
men.1 2 Characterised by progressive inflammatory synovitis,
RA erodes articular cartilage and marginal bone and destroys
joint structure and function,3 leaving patients with joint
deformities, movement problems, and activity limitations.
Within 10 years of disease onset, severe disability occurs in
more than 50% of patients, and only 40–50% are able to
work.4 5 After 20 years of persistent active RA, nearly 80% of
people are partially disabled and 19% are completely
disabled.6 In most cases, irreversible cartilage loss begins
within a year of onset, with 70% of patients exhibiting
radiographic disease progression after three years.7–9 For this
reason, early diagnosis and aggressive treatment are now
recognised as essential to the successful long term outcome of
the disease.10–12
Although traditional treatments for RA such as non-
steroidal anti-inflammatory drugs (NSAIDs) and cortico-
steroids have some benefit for temporary symptomatic
relief,11 dramatic improvements in disease control have
been noted with the use of traditional disease modifying
antirheumatic drugs (DMARDs) such as methotrexate
(MTX),13 which has been reported to slow the progression
of joint destruction.14 15 Inadequate responders to MTX are
often given MTX in combination with other agents, parti-
cularly hydroxychloroquine, sulfasalazine, leflunomide, and
cyclosporin.15 16
In recent times, biological DMARD treatments for RA have
been developed to inhibit the activity of proinflammatory
cytokines such as tumour necrosis factor a (TNFa), which
mediates the destructive synovitis that is the hallmark of RA.
These agents have been successful in treating patients with
RA who fail to respond adequately to traditional DMARD
treatments or who cannot tolerate their toxic side effects.17–20
Two biological DMARDs designed to inhibit TNFa bioactivity
have been approved by the European Medicine Evaluation
Agency (EMEA) and the US Food and Drug Administration
(FDA) for the treatment of RA: etanercept, a soluble TNF
receptor—immunoglobulin G1 (IgG1) fusion protein (which
also binds to TNFb (lymphotoxin)),21–23 and infliximab, a
chimeric (25% mouse/75% human) monoclonal antibody.24–27
Both agents are indicated for the treatment of moderate to
severe DMARD refractory RA.28 29 Etanercept is administered
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Abbreviations: ACR, American College of Rheumatology; AEs, adverse
events; ANAs, antinuclear antibodies; ANCOVA, analysis of
covariance; CRP, C reactive protein; CTC, Common Toxicity Criteria;
DAS, disease activity score; DMARDs, disease modifying antirheumatic
drugs; dsDNA, double stranded DNA; ESR, erythrocyte sedimentation
rate; HAQ, Health Assessment Questionnaire; ITT, intention to treat;
MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RA,
rheumatoid arthritis; sc, subcutaneously; SJC, swollen joint count; TJC,
tender joint count; TNFa, tumour necrosis factor a
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subcutaneously (sc), whereas infliximab is given intra-
venously and only in combination with MTX.28 29
Adalimumab (D2E7; Abbott Laboratories, Abbott Park,
Illinois, USA) is the first fully human anti-TNFa monoclonal
antibody to enter clinical trials for the treatment of RA.
Adalimumab is an IgG1, engineered using phage display
technology with amino acid sequences from the human germ
line, making it indistinguishable in structure and function
from natural human IgG1.30–33 It has high specificity and
affinity for TNFa (Kd = 6610
210 M) but not TNFb; it has a
terminal half life comparable with that of human IgG1
(about two weeks).33 34 Additionally, adalimumab was devel-
oped to have a low degree of immunogenicity, enabling long
term administration, with or without the concurrent use of
immunosuppressant drugs such as MTX, and a low incidence
of allergic reactions.33















Age, years 50.2 (11.9) 53.7 (13.3) 52.6 (11.6) 53.2 (12.3) 53.2 (12.4) 52.4 (12.3)
Female, No (%) 57 (81) 61 (85) 57 (81) 50 (69) 168 (78) 225 (79)
RA duration, years 9.4 (6.6) 10.4 (7.3) 10.0 (7.0) 10.1 (7.9) 10.2 (7.4) 10.0 (7.2)
RF positivity, No (%) 59 (84) 61 (85) 64 (91) 54 (75.0) 179 (84) 238 (84)
Pretreatment AEs, No (%) 38 (54) 47 (65) 44 (63) 47 (65) 138 (65) 176 (62)
Prior DMARDs, n 3.54 4.07 3.67 3.71 3.82 3.75
Patients undergoing previous joint procedure, No (%)` 28 (40) 42 (58) 31 (44) 38 (53) 111 (52) 139 (49)
Patients receiving NSAIDs at baseline, No (%) 56 (80) 55 (76) 57 (81) 56 (78) 168 (79) 224 (79)
Corticosteroids, No (%) 54 (77) 55 (76) 9 (70) 54 (75) 158 (74) 212 (75)
TJC (0–68), n 30.9 (13.1) 31.7 (13.2) 31.0 (12.3) 32.5 (12.8) 31.7 (12.7) 31.5 (12.8)
SJC (0–66), n 20.2 (7.4) 19.6 (9.0) 18.7 (7.7) 19.6 (8.3) 19.3 (8.3) 19.5 (8.1)
Patient assessment of pain (scale, 0–100 mm on VAS)1 72.4 (18.6) 73.1 (18.0) 73.4 (19.4) 67.9 (23.1) 71.5 (20.4) 71.7 (19.9)
Patient global assessment of disease activity
(scale 0–100 mm on VAS)
73.5 (19.3) 74.0 (19.9) 75.7 (19.5) 69.3 (24.2) 73.0 (21.4) 73.1 (20.8)
Doctor global assessment of disease activity
(scale 0–100 mm on VAS)
65.4 (17.8) 65.6 (17.6) 64.8 (18.2) 63.9 (20.6) 64.8 (18.8) 64.9 (18.5)
Disability index of the HAQ (scale 0 to 3)** 1.63 (0.67) 1.79 (0.64) 1.74 (0.66) 1.66 (0.73) 1.73 (0.68) 1.71 (0.67)
CRP, mg/l 63 (44) 57 (40) 56 (39) 60 (55) 58 (45) 59 (45)
ESR, mm/1st h 53.6 (27.9) 52.9 (31.0) 51.7 (27.4) 50.7 (24.8) 51.8 (27.7) 52.2 (27.7)
DAS28 (scale 2–10) 7.1 (0.8) 7.0 (1.0) 7.1 (0.8) 7.0 (1.0) 7.0 (0.9) 7.0 (0.9)
RA, rheumatoid arthritis; RF, rheumatoid factor; AE, adverse event; DMARD, disease modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug;
RF, rheumatoid factor; TJC, tender joint count; SJC, swollen joint count; VAS, visual analogue scale; CRP, C reactive protein; ESR, erythrocyte sedimentation rate;
DAS28, disease activity score 28.
*Values are mean (SD) unless indicated otherwise; mean; `includes total hip replacement, total knee replacement, synovectomy (hand, wrist, and knee), and
radiotherapeutic procedure; 10 = no pain; 100 = severe pain; 0 = no disease activity; 100 = extreme disease activity; **0 = no difficulty; 3 = unable to perform
activity; higher score indicates greater disease activity.
Figure 1 Disposition of patients.
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Early phase I trials have demonstrated that adalimumab
produces rapid and significant responses in patients with
DMARD refractory active RA and suppresses long term
radiological progression.35 36 Previously presented unpub-
lished reports and published sources suggest that adalimu-
mab may be effective both as monotreatment and as
combination treatment with MTX for the treatment of
RA.17 18 37–46 The current trial was conducted to evaluate the
efficacy, dose response, safety, and tolerability of sc injections
of adalimumab given weekly as monotreatment in patients




This phase II study was a 12 week, double blind, placebo
controlled, multicentre trial conducted at 25 sites across nine
European countries in accordance with the Good Clinical
Practice Guidelines and principles of the Declaration of
Helsinki. The ethics committee at each study site approved
the study protocol. Patients were required to provide written
informed consent.
After being screened for eligibility, patients discontinued
all DMARDs four weeks before receiving the first injection of
the study drug. Participants using over the counter prepara-
tions, NSAIDs, or oral corticosteroids (maximum daily dose
equivalent of 10 mg of oral prednisone9 10) before screening
were allowed to continue using them at pre-enrolment doses.
The use of analgesics such as propoxyphene, codeine,
acetaminophen plus codeine, or aspirin for pain relief was
permitted.
Patients were randomised 1:1:1:1 to receive weekly sc
injections of adalimumab (20, 40, or 80 mg) or placebo.
Patients were instructed on proper self injection techniques
and self administered the study drug. Off site self adminis-
tration of the study drug continued throughout the study,
with the exception of study visits, during which patients self
administered adalimumab or placebo under supervision of
study personnel.
After completing the 12 week study, patients entered a 40
week blinded continuation period, during which they were
given the same weekly dose of adalimumab. Patients in the
placebo group were switched to adalimumab 40 mg. Patients
completing the 40 week period entered an open label
continuation period, during which they received the same
weekly doses of 40 mg adalimumab for another year. This
report presents the results of the 12 week placebo controlled
period. The results of the 40 week and 52 week continuation
studies will be presented separately.
Table 2 American College of Rheumatology (ACR) response to treatment at weeks 2 and















Week 2 2 (3) 22 (31) 27 (39) 33 (46) 82 (38)
Week 12 7 (10) 36 (51) 40 (57) 39 (54) 115 (54)
>50% (ACR50)
Week 2 0 (0) 2 (3) 4 (6) 5 (7) 11 (5)
Week 12 1 (1) 17 (24) 19 (27) 14 (19) 50 (23)
>70% (ACR70)
Week 2 0 (0) 0 (0) 1 (1) 1 (1) 2 (1)
Week 12 0 (0) 8 (11)` 7 (10)` 6 (8)1 21 (10)`
*Group numbers indicate initial size of each group, with the exception of the adalimumab 20 mg group, which
does not include the patient with Felty’s syndrome who was withdrawn after the first dose. Withdrawals and
rescues were considered treatment failures.
Comparison v placebo (Pearson’s two sided x2 test, a= 0.05): p(0.001; `p(0.01; 1p(0.05.
Figure 2 Time course of American College of Rheumatology responses.
(A) ACR20 response; (B) ACR50 response; (C) ACR70 response.
Student’s paired t test for paired observations: *p = 0.01 v baseline;
p = 0.01 v baseline; `p = 0.05 v baseline.
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Patients with unbearable disease activity (a subjective
condition determined by the patient and investigator) who
completed at least eight weeks of the 12 week placebo
controlled study were allowed to enter a rescue arm for the
remainder of the study, during which they received increased
doses of NSAIDs, corticosteroids, or other non-investigational
agents; however, patients entering the rescue arm were not
permitted to receive adalimumab until the end of the
12 weeks. Those who participated beyond week 12 were
given open label adalimumab.
Patients
Patients 18 years of age or older were eligible for this study if
they had a diagnosis of RA according to the revised 1987
American College of Rheumatology (ACR) criteria47 and
active inflammatory synovitis, defined by a tender joint
count (TJC) of >12 and swollen joint count (SJC) of >10
based on an examination of 68 and 66 assessed joints,
respectively, and either an erythrocyte sedimentation rate
(ESR) of >28 mm/1st h or a serum C reactive protein (CRP)
level >20 mg/l. Only patients for whom treatment had failed
with at least one traditional DMARD were eligible.
Exclusion criteria included joint surgery within two
months before screening or an episode of infection requiring
admission to hospital within 30 days before study entry.
Treatment with either intra-articular or intramuscular
corticosteroids within four weeks of prescreening or an
investigational chemical or biological drug within two or six
months, respectively, of prescreening were exclusionary
criteria. Additionally, patients with impaired renal or hepatic
function or an abnormal serum profile were excluded from
the study. Patients’ body weight could not exceed 100 kg.
Women of childbearing potential required a negative
pregnancy test; the use of a reliable contraceptive method
was mandatory.
Efficacy assessment
Clinical and laboratory efficacy assessments were conducted
at screening, baseline, and two week intervals. ACR core
criteria were monitored at each study visit: TJC and SJC;
patient assessments of pain, disease activity, and disability
(Disability Index of the Health Assessment Questionnaire
(HAQ)48); doctor global assessment of disease activity; ESR;
and CRP.49 50
The primary measure of efficacy was the number of
patients meeting ACR20 response criteria at week 12.
Patients were classified as responders if they fulfilled the
ACR20 core criteria for a clinical response to treatment (that
is, >20% improvement in TJC and SJC plus >20% improve-
ment in three or more of the following five criteria: patient
assessment of pain, patient global assessment of disease
activity, doctor global assessment of disease activity, patient
assessment of disability (Disability Index of the HAQ), and
CRP).50
Secondary evaluations of efficacy included ACR50 and
ACR70, defined in the same manner as ACR20 but with
>50% or >70% degree of improvement, respectively. Other
secondary outcomes were TJC, SJC, a battery of disease
activity and health assessments, including the disease activity
score 28 (DAS28), ESR, and CRP.49 50
Safety assessment
A complete physical examination was performed at study
entry (screening), baseline, every two weeks, and, for those
patients who withdrew, up to six months of follow up after
the last study dose. Patients were monitored for vital signs
and by electrocardiogram and laboratory tests, including
haematology evaluations, serum chemistry (including a non-
fasting lipid profile), coagulation parameters, and urine
analysis. Additionally, serum was evaluated for the presence
of antinuclear antibodies (ANAs), anti-double stranded DNA
(anti-dsDNA) antibodies (if ANA levels were increased from
baseline), and serum anti-adalimumab antibodies. ANA
analysis was performed by an indirect immunofluorescence
technique on HEp-2 cells. A positive ANA titre was defined as
>1/80. Anti-dsDNA positivity was established at .25 kU/l
by an anti-DNA radioassay. Serum samples were analysed
for anti-adalimumab antibodies using a validated double
antigen, enzyme linked immunosorbent assay (ELISA). A
positive anti-adalimumab signal was defined as a concentra-
tion exceeding 20 ng/ml that could not be suppressed by
>50% after the addition of 10% human serum to a sample.
ANAs were measured at study entry, baseline, and monthly
thereafter, and anti-adalimumab antibodies were measured
at all scheduled study visits.
Data on adverse events (AEs), such as type, time of
occurrence, time to resolution, severity, and causal relation-
ship to treatment, were collected at the baseline visit and at
each subsequent study visit. When appropriate, AEs and
laboratory values were graded according to the Common
Toxicity Criteria (CTC) of the National Cancer Institute
(grade 1 = mild; grade 2 = moderate; grade 3 = severe; and
grade 4 = life threatening or intractable). Laboratory AEs
were automatically generated from CTC grade changes
regardless of their clinical relevance. Additionally, AEs
necessitating or prolonging hospitalisation, placing the
patient at risk of death, or resulting in death, permanent or
significant disability, congenital anomaly/birth defect, or
other medically important conditions were categorised as
serious AEs.
Statistical analysis
Assuming an ACR20 response rate of 20%, 90% power, and a
drop out rate of 10%, a sample size of 64 patients in each
treatment arm was required. Statistical significance was set
at p(0.05 for all tests. The study was not powered to show a
difference between treatment groups. Demographic and
baseline characteristics were summarised by descriptive
statistics, and treatment group comparability at baseline
Table 3 Mean time (weeks) to achieving response according to the American College of
Rheumatology (ACR)
Degree of improvement Placebo (n = 70)*
Adalimumab
20 mg (n = 71)* 40 mg (n = 70)* 80 mg (n = 72)*
>20% (ACR20) 6.6 4.0 4.1 3.7
>50% (ACR50) 10.0 7.4 5.9 5.3
>70% (ACR70) NA 7.8 7.0 6.9
NA, not applicable.
*Group numbers indicate initial size of each group, with the exception of the adalimumab 20 mg group, which
does not include the patient with Felty’s syndrome who was withdrawn after the first dose. Withdrawals and
rescues were considered treatment failures.
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was determined using appropriate statistical tests. Efficacy
analyses were performed for the intention to treat (ITT)
population, defined as all randomised patients who received
at least one double blind injection of study drug and for
whom any assessment of efficacy under double blind
conditions was available. One patient with Felty’s syndrome
was excluded from the ITT population despite receiving a
single injection of adalimumab 20 mg. No efficacy assess-
ments under double blind conditions were available for this
patient.
The response rates of the primary efficacy end point
(ACR20 at week 12) for the adalimumab groups were
compared with that of placebo using two sided Pearson’s x2
tests, with a= 0.05. The closure principle was applied to take
multiplicity of testing into account. The tests were performed
sequentially versus placebo in order of descending adalimu-
mab dose. Test results were considered to be significant if the
p value of this test and the p values of all preceding tests were
(0.05. Patients not completing the 12 week trial (that is,
those who were withdrawn or required rescue) despite
fulfilling ACR criteria were considered non-responders.
Primary and all secondary efficacy end points were sum-
marised using descriptive statistics (that is, statistical
characteristics, frequencies, percentages, confidence inter-
vals). Descriptive treatment group comparisons between
groups receiving adalimumab and placebo were performed
at week 12 using two sided Pearson’s x2 tests and analysis of
covariance (ANCOVA). Within each treatment group,
improvements from baseline in the seven ACR core criteria
were evaluated at each time point for possible significant
differences using the Student t test for paired observations.
All patients randomly allocated to receive adalimumab and
who received at least one dose of adalimumab were included
in the safety analyses. Vital signs and laboratory measures
Table 4 American College of Rheumatology (ACR) core response criteria: baseline values and mean absolute changes from
baseline to weeks 2 and 12*
ACR criterion Placebo (n = 70)`
Adalimumab
20 mg (n = 71)` 40 mg (n = 70)` 80 mg (n = 72)` All doses (n = 213)`
Tender joint count (0–68), n
Baseline 30.9 (13.1) 31.7 (13.2) 31.0 (12.3) 32.5 (12.8) 31.7 (12.7)
Change from baseline*
Week 2 21.0 (10.1) 27.7 (11.1)1 29.5 (10.7)1 211.4 (12.0)1 29.5 (11.3)1
Week 12 25.1 (17.8) 214.0 (14.1)1 215.3 (11.6)1 215.2 (12.3)1 214.8 (12.7)1
Swollen joint count (0–66), n
Baseline 20.2 (7.4) 19.6 (9.0) 18.7 (7.7) 19.6 (8.3) 19.3 (8.3)
Change from baseline*
Week 2 20.9 (5.0) 24.6 (7.2)1 25.0 (6.0)1 25.4 (7.6)1 25.0 (6.9)1
Week 12 22.8 (7.3) 28.1 (8.2)1 29.6 (7.1)1 210.7 (7.5)1 29.5 (7.6)1
Patient assessment of pain (scale 0–100 mm on VAS)
Baseline 72.4 (18.6) 73.1 (18.0) 73.4 (19.4) 67.9 (23.1) 71.5 (20.4)
Change from baseline*
Week 2 21.7 (22.3) 225.8 (26.4)1 226.0 (25.3)1 226.2 (20.8)1 226.0 (24.2)1
Week 12 27.8 (26.9) 231.8 (28.7)1 235.3 (29.4)1 230.1 (22.1)1 232.3 (26.7)1
Patient global assessment of disease activity (scale 0–100 mm on VAS)**
Baseline 73.5 (19.3) 74.0 (19.9) 75.7 (19.5) 69.3 (24.2) 73.0 (21.4)
Change from baseline*
Week 2 21.3 (20.5) 224.2 (25.9)1 226.6 (29.6)1 226.8 (22.2)1 225.8 (24.6)1
Week 12 26.9 (26.0) 231.7 (28.0)1 237.6 (27.9)1 231.0 (23.7)1 233.3 (26.5)1
Doctor global assessment of disease activity (scale 0–100 mm on VAS)**
Baseline 65.4 (17.8) 65.6 (17.6) 64.8 (18.2) 63.9 (20.6) 64.8 (18.8)
Change from baseline*
Week 2 22.3 (18.4) 219.6 (18.9)1 220.7 (22.8)1 224.3 (20.4)1 221.5 (20.7)1
Week 12 25.0 (22.0) 228.8 (23.3)1 235.7 (20.3)1 233.4 (21.1)1 232.6 (21.7)1
Disability Index of the HAQ (scale 0–3)
Baseline 1.63 (0.67) 1.79 (0.64) 1.74 (0.66) 1.66 (0.73) 1.73 (0.68)
Change from baseline*
Week 2 +0.05 (0.38) 20.34 (0.42)1 20.28 (0.33)1 20.30 (0.45)1 20.31 (0.40)1
Week 12 20.04 (0.37) 20.45 (0.461 20.47 (0.43)1 20.48 (0.50)1 20.46 (0.46)1
CRP, mg/l
Baseline 63 (44) 57 (40) 56 (39) 60 (55) 58 (4.5)
Change from baseline*
Week 2 22 (35) 230 (41)1 229 (30)1 235 (44)1 231 (39)1
Week 12 21 (3.4) 224 (3.1)1 232 (3.4)1 234 (35)1 230 (33)1
ESR, mm/1st h
Baseline 53.6 (27.9) 52.9 (0.7) 51.7 (27.4) 50.7 (24.8) 51.8 (27.7)
Change from baseline*
Week 2 +2.5 (16.7) 214.8 (20.8)1 214.3 (18.1)1 215.7 (18.1)1 214.9 (19.0)1
Week 12 22.0 (20.1) 214.2 (21.8)`` 217.9 (20.0)1 217.3 (20.6)1 216.4 (20.8)1
DAS28 (scale, 2–10)11
Baseline 7.1 (0.8) 7.0 (1.0) 7.1 (0.8) 7.0 (1.0) 7.0 (0.9)
Change from baseline*
Week 2 20.0 (0.7) 21.1 (1.0)1 21.4 (1.1)1 21.5 (1.0)1 21.3 (1.0)1
Week 12 20.5 (1.1) 21.8 (1.4)1 22.1 (1.3)1 22.0 (1.2)1 22.0 (1.3)1
VAS, visual analogue scale; HAQ, Health Assessment Questionnaire; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; DAS28, disease activity score
28; ANCOVA, analysis of covariance.
*A negative absolute change indicates a decrease in mean values from baseline to weeks 2 or 12 and an improvement in that parameter; a positive absolute
change indicates an increase in mean values from baseline and a worsening in that parameter; Results are shown as mean (SD); `group numbers indicate initial
size of each group, with the exception of the adalimumab 20 mg group, which does not include the patient with Felty’s syndrome who was withdrawn after the first
dose. Withdrawals and rescues were considered treatment failures; 1p(0.001 v placebo (ANCOVA); 0 = no pain; 100 = severe pain; **0 = no disease activity,
100 = extreme disease activity; 0 = no difficulty, 3 = unable to perform activity; ``p(0.01 v placebo (ANCOVA); 11higher score indicates greater disease
activity.
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were described by statistical characteristics and by the
frequency of abnormal values. AEs were analysed by
frequency and reported as percentages of patients by
randomised treatment.
RESULTS
Demographic and baseline characteristics
The demographic and baseline characteristics of the study
population (table 1) were similar for all treatment groups.
Patients ranged in age from 22 to 83 years, with an overall
mean age of 52.4 years. Most patients were women (79%),
and the majority were white (99%). The mean duration of RA
was 10.0 years, and baseline TJC and SJC averaged 31.5 and
19.5, respectively. The baseline HAQ score was 1.71 and the
baseline DAS28 was 7.0. CRP and ESR values (59 mg/l and
52.2 mm/1st h, respectively) substantially exceeded normal
levels. Patient and doctor based assessments of disease
activity and patient assessment of pain were 73.1, 64.9, and
71.7, respectively. Nearly 90% of patients reported one or
more concomitant diseases. Before the study, all patients had
used at least one DMARD (mean 3.75), with more than half
(50.3%) having used from four to eight different DMARDs.
The most commonly reported previously used DMARDs were
MTX (92%), sulfasalazine (69%), parenteral gold (60%),
chloroquine/hydroxychloroquine (48%), azathioprine (32%),
penicillamine (30%), cyclosporin (29%), oral gold (17%), and
cyclophosphamide (6%).
Patient disposition
Of the 323 patients enrolled, 284 were randomly allocated to
receive weekly sc injections of adalimumab 20 mg (n = 72),
40 mg (n = 70), or 80 mg (n = 72) or placebo (n = 70) (fig 1).
The ITT population included all but the previously mentioned
participant with Felty’s syndrome, who was withdrawn from
the study after receiving one sc injection of adalimumab
20 mg. No efficacy assessments under double blind conditions
were available for this patient. Two hundred and thirty
three patients completed the study—186 (87%) patients in
the adalimumab groups and 47 (67%) in the placebo group.
Similar proportions of patients in the adalimumab and
placebo groups were withdrawn during the study, 11/214
(5%) and 2/70 (3%) patients, respectively. From the
adalimumab 20 mg group, 2 (3%) patients were withdrawn
because of lack of efficacy and 1 (1%) patient because of
protocol deviation and withdrawal of consent. From the
adalimumab 40 mg group, 3 (4%) patients were withdrawn
because of AEs (fever, raised ANA titres, gastrointestinal
disorder) and 1 (1%) patient withdrew consent. The patient
with raised ANA titres (of grade 3 severity and a maximum
titre of 1/1280 at the time of withdrawal) was withdrawn
because the investigator concluded that the condition was
related to treatment with the study drug. Two (3%) patients
in the adalimumab 80 mg group had AE related withdrawals
(surgery, anxiety), and 1 (1%) patient in this group died from
a myocardial infarction on day 86. Reasons for the 2 (3%)
placebo withdrawals were AEs (vasculitis/paralysis/pain) and
lack of efficacy. A greater proportion of patients in the
placebo group (21, 30%) required rescue during the 12 week
study period because of uncontrolled disease activity than
those receiving adalimumab (17, 7.9%).
Efficacy assessments
ACR response
The ACR20 response was significant for each adalimumab
group at each evaluation throughout the study relative to
placebo (p(0.01 for all comparisons, two sided Pearson’s x2
test) (table 2, fig 2A), with 71% (82/115) of the ultimate
ACR20 response rate to adalimumab treatment being
achieved at week 2. At week 12, 36 (51%), 40 (57%), and
39 (54%) patients treated with adalimumab 20, 40, and
80 mg, respectively, were ACR20 responders, compared with
7 (10%) placebo patients. Maximal ACR20 response rates for
Table 5 Overview of adverse events (AEs). Results are shown as the number (%) of patients
Placebo (n = 70)
Adalimumab
20 mg (n = 72) 40 mg (n = 70) 80 mg (n = 72) All doses (n = 214)
Patients with:
Serious AE 7 (10) 2 (3) 5 (7) 9 (13) 16 (7)
Severe or intractable AE 19 (27) 8 (11)` 11 (16) 14 (19) 33 (15)`
Serious infection 0 (0) 0 (0) 2 (3) 2 (3) 4 (2)
Malignancy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Most frequently reported (10%) AEs
Laboratory test abnormal* 39 (56) 33 (46) 35 (50) 29 (40) 97 (45)
Hypercholesterolaemia (cholesterol .6.21 mmol/l) 24 (34) 32 (44) 29 (41) 31 (43) 92 (43)
Haemoglobin Q 31 (44) 23 (32) 27 (39) 25 (35) 75 (35)
Haemorrhage 23 (33) 16 (22) 19 (27) 15 (21) 50 (23)
Hyperlipidaemia (triglycerides .2.26 mmol/l) 13 (19) 18 (25) 22 (31) 22 (31) 62 (29)
Injection site reaction 4 (6) 21 (29) 16 (23)1 21 (29) 58 (27)
Hyperuricaemia (uric acid 0.42 mmol/l (men),
.5.7 mmol/l (women))
15 (21) 13 (18) 16 (23) 19 (26) 48 (22)
Haematuria (blood urea .500 mg/l) 18 (26) 16 (22) 17 (24) 9 (13) 42 (20)
Blood urea nitrogen increased 6 (9) 11 (15) 12 (17) 12 (17) 35 (16)
Clinical flare 11 (16) 5 (7) 6 (9) 6 (8) 17 (8)
Rhinitis 7 (10) 11 (15) 11 (16) 7 (10) 29 (14)
Alkaline phosphatase increased 10 (14) 10 (14) 6 (9) 10 (14) 26 (12)
Alanine transaminaseq 6 (9) 6 (8) 1 (1) 10 (14) 17 (8)
Hypophosphataemia (phosphate ,0.8 mmol/l) 4 (6) 0 (0) 9 (13) 4 (6) 13 (6)
Rash 6 (9) 7 (10) 9 (13) 8 (11) 24 (11)
Cough increased 2 (3) 9 (13) 5 (7) 3 (4) 17 (8)
Pruritus 4 (6) 9 (13) 8 (11) 9 (13) 26 (12)
Headache 3 (4) 9 (13) 8 (11) 3 (4) 20 (9)
Hyperkalaemia (potassium .5 mmol/l) 5 (7) 8 (11) 4 (6) 7 (10) 19 (9)
Proteinuria (urine protein 0.15 g/24 h) 0 (0) 5 (7) 7 (10)` 4 (6) 16 (7)`
Hyponatraemia (sodium ,135 mmol/l) 7 (10) 7 (10) 7 (10) 5 (7) 19 (9)
*Changes in common toxicity criteria grade automatically generated laboratory AEs irrespective of the investigator’s opinion about their clinical relevance;
erythema and/or itching, haemorrhage, pain, or swelling at injection site.
Comparison v placebo (Fisher’s exact test): `p(0.05; 1p(0.01; p(0.001.
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the adalimumab 20, 40, and 80 mg groups were reached at
week 12 (36, 51%), week 10 (44, 63%), and weeks 6 and 12
(39, 54%), respectively.
ACR50 response rates for the adalimumab 40 and 80 mg
groups were statistically better than those for placebo
(p(0.05) at any given study visit, and for the 20 mg group
at week 4 and all subsequent study visits. Fifty eight percent
(29/50) of the ultimate ACR50 response rate was achieved at
week 4. At week 12, 17 (24%), 19 (27%), and 14 (19%)
patients in the adalimumab 20, 40, and 80 mg groups,
respectively, had an ACR50 response, compared with 1 (1%)
patient in the placebo group (p(0.001 for all comparisons)
(table 2, fig 2B). Maximal ACR50 response for the adalimu-
mab groups (by ascending dose) was attained by week 12
(17, 24%), week 10 (20, 29%), and week 8 (14, 19%),
respectively.
ACR70 responses at week 6 reached significance versus
placebo for the two lower doses of adalimumab and at week
10 for the highest dose. At week 12, all adalimumab doses
were associated with statistically significant ACR70 response
relative to placebo: 8 (11%), 7 (10%), and 6 (8%) patients in
the 20, 40, and 80 mg groups, respectively (p(0.01; p(0.01;
p(0.05, respectively) (table 2, fig 2C). No patients receiving
placebo attained an ACR70 response. Maximal responses for
the treatment groups receiving adalimumab 20, 40, and
80 mg were reached at week 12 (8, 11%), week 10 (9, 13%),
and week 12 (6, 8%), respectively.
ACR responders in all adalimumab groups achieved ACR
response status more rapidly than the placebo responders
(table 3). The mean times to the onset of ACR responses were
dose dependent, with the adalimumab 20 and 40 mg groups
having similar mean times to the onset of ACR20 response
and the 80 mg group having a somewhat shorter time. The
mean times to meeting ACR50 and ACR70 criteria also were
dose dependent.
ACR core criteria
Treatment with all doses of adalimumab resulted in rapid,
significantly improved signs and symptoms of RA relative
to placebo, as assessed by improvements in ACR core
criteria (p(0.01 v placebo for all comparisons, ANCOVA)
(table 4).
Patients experienced an immediate, rapid decline in mean
TJC after the initial injection of adalimumab. At week 2,
mean reductions of 7.7, 9.5, and 11.4 were reported for the
adalimumab 20, 40, and 80 mg groups, respectively; the
placebo group showed little improvement (that is, a mean
decrease of 1.0). All adalimumab groups exhibited significant
improvement in TJC at each subsequent evaluation, with
actual reductions of 14.0, 15.3, and 15.2, respectively, at week
12, representing mean changes of 44.2%, 49.4%, and 46.8%,
respectively (p(0.001 v placebo for all comparisons).
A similar degree of rapid clinical improvement was shown
by the immediate decline in the mean number of swollen
joints in patients receiving adalimumab. By week 2, all
adalimumab groups attained significant mean reductions in
SJC from baseline—4.6, 5.0, and 5.4 for adalimumab 20, 40,
and 80 mg, respectively, compared with 0.9 for placebo.
Actual decreases in SJC at week 12 averaged 8.1, 9.6, and
10.7, respectively, representing improvements of 41.3%,
51.3%, and 54.6%, respectively (p(0.001 v placebo for all
comparisons). Patients receiving placebo showed little
improvement in SJC at week 12 (mean decrease of 2.8,
13.9%).
HAQ Disability Index scores for adalimumab decreased
significantly from the first evaluation to the end of the study.
Decreases in HAQ scores at week 2 averaged 0.34, 0.28, and
0.30 for adalimumab 20, 40, and 80 mg, respectively,
compared with an increase of +0.05 for placebo, indicating
worsening of disability. Mean HAQ Disability Index scores
continued to decrease for all adalimumab groups up to week
12, with reductions of 0.45, 0.47, and 0.48, respectively
(p(0.001 v placebo for all comparisons) and 0.04 for placebo.
At each assessment, significantly lowered CRP concentra-
tions were reported for all adalimumab groups, with
reductions at week 12 reaching 24, 32, and 34 mg/l for
adalimumab 20, 40, and 80 mg, respectively (p(0.001 v
placebo for all comparisons) and little change for placebo.
Additionally, significant reductions in mean ESR from
baseline occurred at week 2 (p(0.001 v placebo for all
comparisons). By week 12, ESR values had decreased 14.2,
17.9, and 17.3 mm/1st h for adalimumab treatment groups
by ascending doses (p(0.01, p(0.001, p(0.001 v placebo
for adalimumab 20, 40, and 80 mg, respectively) and by
2.0 mm/1st h for placebo.
Patient and doctor global assessments of disease activity
and patient assessment of pain for all adalimumab groups
significantly improved at each study visit (p(0.001 v placebo
for all comparisons).
Laboratory results
Clinically significant improvements occurred in several
haematological laboratory values in adalimumab patients,
including increased haemoglobin, packed cell volume, and
percentages of lymphocytes as well as decreased platelet
counts, fibrinogen levels, and percentages of neutrophils
(data not shown).
Safety assessments
Table 5 presents an overview of AEs, including those that
occurred most frequently (>10%) by treatment group. The
most commonly reported treatment related AE was labora-
tory test abnormality, particularly decreased lymphocytes,
which occurred with marked difference (>10% more
frequently) in patients randomised to placebo (39, 56%)
compared with those randomised to adalimumab (97, 45%).
Two AEs occurred in adalimumab patients with 10% or
greater frequency than with placebo. Reactions occurring at
the injection site—erythema and/or itching, haemorrhage,
swelling, or pain—were reported in 21 (29%), 16 (23%), and
21 (29%) patients receiving adalimumab 20, 40, and 80 mg,
respectively, versus 4 (6%) patients randomised to placebo
(p(0.01 v placebo for all comparisons). Hyperlipidaemia
(triglycerides .2.26 mmol/l was reported in 18 (25%), 22
(31%), and 22 (31%) patients receiving adalimumab 20, 40,
and 80 mg, respectively, versus 13 (19%) patients receiving
placebo. None of the commonly reported treatment emergent
AEs showed a dose-response relationship to adalimumab.
Figure 3 Improvement in American College of Rheumatology core
criteria at 12 weeks with adalimumab 40 mg. Student’s t test for paired
observations: p = 0.001 v baseline.
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The occurrence of serious AEs with adalimumab did not
exceed that with placebo—16 (7%) versus 7 (10%), respec-
tively. Serious infections occurred in 4 (2%) patients in the
adalimumab dose groups. In the adalimumab 40 mg group, 1
(1%) patient had a gastrointestinal disorder of an infectious
nature and 1 (1%) had mild bronchitis. Two (3%) patients
receiving adalimumab 80 mg developed serious infections,
one a urinary tract infection and the other a bacterial
infection with fever. Both infections were deemed by
investigators as possibly related to adalimumab treatment,
and the patients were withdrawn from the study, each
requiring additional drugs and admission to hospital. (The
source of the bacterial infection was never identified and the
fever subsided after five days of antibiotic treatment.) All
serious infections resolved or were resolving by week 12. A
fatal myocardial infarction occurred on day 86 of the study in
a 65 year old man with pre-existing cardiac disease who was
randomised to adalimumab 80 mg and was receiving a
concomitant antihypertensive drug. The investigator judged
the death unlikely to be related to the study drug. No drug
related toxicity was indicated by haematology, coagulation,
clinical chemistry, or urine analysis evaluations.
During the study, changes in ANA status—from baseline
negative to positive and from baseline positive to negative—
were seen commonly at all evaluations. Among the 283
patients (adalimumab = 213, placebo = 70) evaluated for
ANA status during the study, 37/71 (52%), 29/70 (41%),
and 34/72 (47%) patients in the 20 mg, 40 mg, and 80 mg
adalimumab groups, respectively, had ANA positivity (titres
>1/80) compared with 26/70 (37%) patients in the placebo
group. Of the adalimumab treated patients testing positive to
ANAs (n = 100), 3 (3%) patients also tested positive to anti-
dsDNA antibodies (that is, .25 kU/l): 1/37 (3%) and 2/34
(6%) patients in the 20 and 80 mg groups, respectively. No
patients in the placebo group tested positive to anti-dsDNA
antibodies. No patients developed lupus-like syndrome, and
no malignancies were reported. During the study, anti-
adalimumab antibodies were detected in the sera of four
patients.
DISCUSSION
Adalimumab is the first fully human monoclonal antibody to
TNFa to enter clinical trials for the treatment of RA. Early
phase I/II trial results with adalimumab monotreatment have
been very encouraging.17 18 34 37 39
The current study was designed to evaluate the effective-
ness, dose response, safety, and tolerability of weekly sc
injections of various doses of adalimumab under placebo
controlled conditions. Study participants generally had
severe, recalcitrant, long term RA. Despite prior treatment
with an average of nearly four traditional DMARDs, these
patients continued to exhibit persistent disease activity,
including large numbers of tender and swollen joints, thus
placing them at risk of further joint destruction and
worsening disability.
Patients receiving adalimumab experienced significantly
better improvement in their physical condition, evidenced by
the statistically significant ACR20 and ACR50 responses at
virtually all study assessments for each adalimumab group
compared with placebo. At the 12 week assessment, more
than 50% of patients in each adalimumab group were ACR20
responders and about 20% had attained an ACR50 response.
Additionally, at week 12, all doses of adalimumab produced a
statistically significant ACR70 response versus placebo.
Adalimumab is associated with rapid clinical response
rates. In one study, clinically relevant responses were
reported to occur at 24 hours to one week after a single
intravenous injection of adalimumab.34 In the current study,
sc injections of adalimumab resulted in significantly better
results by the first study assessment at week 2, with the
majority of eventual responders already fulfilling ACR20 or
ACR50 response criteria, compared with 8% of eventual
responders receiving placebo. The mean times to the onset of
ACR20 and ACR50 responses were consistently shorter for all
adalimumab doses than for placebo.
The rapid clinical response to adalimumab treatment also
was shown by the early (that is, week 2) statistically
significant decline in the number of swollen and tender
joints as well as improvements in other ACR core criteria
compared with placebo in the DMARD refractory population.
All improvements were immediate and sustained. More than
half of the progress in disease activity as reflected in the ACR
core criteria occurred within two weeks of the initial dose of
adalimumab. At all subsequent evaluations, all doses of
adalimumab were associated with statistically better
improvements in the ACR core criteria than placebo.
Patient assessed outcomes such as functional status (HAQ),
RA related pain, and global disease activity significantly
improved over the course of treatment with adalimumab.
Here again, enhanced physical functioning, as reflected by
these measures of disease activity, was rapid, with more than
half of the total improvement in scores occurring within the
first two weeks of treatment.
It is also interesting to note that at week 2, adalimumab
treated patient assessments of disease activity, including pain
and physical functioning, were consistently better than
doctor assessed disease activity, even though at baseline,
patients assessed their disease state as being more severe
than did the investigators (73.1 v 64.9, respectively, on the
100 mm visual analogue scale).
In most measures of efficacy at week 12, adalimumab
40 mg was associated with better results than the other
doses. Figure 3 illustrates the improvements in ACR criteria
attained by this group over the entire treatment period.
However, it is important to note that the study was neither
designed nor powered to show statistical differences between
the adalimumab groups. Compared with placebo, all adali-
mumab groups had consistently better ACR responses and
improvements in ACR core criteria from baseline.
Overall, adalimumab was safe and well tolerated at all
doses. AEs commonly occurred in all groups, a finding
consistent with a study group having longstanding active RA.
It should be noted that at baseline, more than half of the
patients had AEs attributable to the disease state or to
concomitant drugs. In general, treatment emergent AEs were
mild or moderate in intensity, and those of a more serious
nature resolved or were resolving by the end of the study. A
65 year old man taking adalimumab 80 mg died of a
myocardial infarction on day 86 of the study. This patient,
who had pre-existing cardiac disease and cardiovascular risk
factors, was at increased risk of myocardial infarction and
was treated with the antihypertensive amlodipine. The
patient’s total cholesterol level was slightly raised
(5.85 mmol/l) at week 12 but was below baseline level
(7.40 mmol/l). The investigator judged the relationship of the
death to the study drug as being unlikely.
The high incidence of laboratory abnormalities—nearly
50% overall—can be attributed to the automatic reporting of
these events whenever changes in CTC grade occurred (which
may have been small departures from normal ranges),
regardless of their clinical relevance.
Reactions at the site of the sc injection are commonly
associated with sc administered drugs used to treat RA.
Clinical trials with other sc administered biological agents in
patients with RA reported injection site reactions of 37%
(etanercept)28 and more than 70% (anakinra).51 In the
current study, injection site reactions occurred with more
statistically significant frequency among adalimumab treated
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patients than placebo treated patients (27% v 6%; p(0.01 v
placebo); but, overall, these reactions were mild and
manageable. Proteinuria also occurred more frequently in
the adalimumab treated patients (7% v 0%; p(0.05 v
placebo); however, no systematic or dose related trends were
seen.
Adalimumab treated patients demonstrated mild increases
in serum lipid levels in comparison with placebo treated
patients. It is difficult to analyse such data because patients
in both groups had blood samples drawn while not fasting,
and the two groups were not matched for dietary intake and
baseline lipid profiles. However, in general, patients with RA,
when untreated, demonstrate altered lipoprotein profiles
(that is, low cholesterol concentrations in all lipoprotein
fractions and low triglyceride concentrations in the very low
density and high density lipoprotein fractions).52 Treatments
that reduce inflammation generally effect normalisation in
these profiles.52 It has been suggested that altered lipid
patterns with untreated active RA may be associated with an
increased risk of atherosclerosis53; therefore, effectively
controlling the inflammatory state in RA may have additional
benefits.54
Because the mechanism of action of cytokine treatments
such as adalimumab is inhibition of an immunologically
active cytokine, these agents can be associated with an
increased incidence of infectious complications. During this
study, patients were carefully monitored for episodes of
serious infection and immunological reactions. The incidence
of serious infections in adalimumab treated patients (2%)
was slightly less than the expected incidence of these events
in patients with RA receiving immunosuppressant drugs
(2.9%).55 No cases of lupus-like syndrome were reported
among patients with an increase in autoantibody produc-
tion. Four patients developed anti-adalimumab antibodies
during the study. Because adalimumab has sequences
that are germline human in the framework regions, it is
expected to have reduced immunogenicity compared with
antibodies that contain sequences derived from non-human
species. Nevertheless, low level anti-idiotypic responses
would be expected based on the theory that human
antibodies may be part of an idiotypic network as described
by Jerne.56
Because of the small number of cases, no overall
conclusions can be drawn about the overall efficacy and
safety of patients who develop anti-adalimumab antibodies.
The three adalimumab doses were similarly tolerated, with
no dose limiting effects between groups in relation to any AE.
The high patient retention rate (87%) among DMARD
refractory patients receiving adalimumab (v 67% for placebo)
indicated that study participants were willing to cope with
occasional side effects as well as with self administration of
the study drug to sustain improved disease control.
In conclusion, adalimumab treatment significantly altered
the course of disease in patients who had considerable
disease activity of long duration and who had not adequately
responded to traditional DMARDs. All adalimumab doses
acted more rapidly and were more efficacious than placebo,
with the 80 mg dose of adalimumab not providing any
additional benefit over the 40 mg dose. Treatment related
reductions in disability plus marked improvements in acute
phase reactants such as CRP and ESR suggest that
adalimumab treatment may halt disease progression.
Recent reports substantiate this outcome among patients
receiving adalimumab monotreatment over a one and two
year period.35 36 Nevertheless, these results need to be
confirmed in large radiographic studies. Adalimumab treat-
ment was safe and convenient, allowing patients to self
administer the sc injections at home. No systemic allergic
reactions were reported with adalimumab treatment,
enabling long term administration without the concurrent
use of immunosuppressant drugs such as MTX.
Patients completing this 12 week placebo controlled study
were subsequently entered into a 40 week blinded continua-
tion study of adalimumab, followed by an open label study
for an additional year in order to validate the chronic efficacy
and safety of adalimumab. The results of these continuation
studies will be presented separately.
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